PF 4895162

Drug Profile

PF 4895162

Alternative Names: PF-04895162

Latest Information Update: 24 Apr 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Antiepileptic drugs
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Epilepsy

Most Recent Events

  • 26 Mar 2013 Pfizer completes a phase I trial in Healthy volunteers in USA (NCT01691274)
  • 31 Oct 2012 Phase-I clinical trials in Epilepsy in USA (PO)
  • 19 Sep 2012 Preclinical trials in Epilepsy in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top